

March 29, 2023

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation of proposed Sale of Subsidiary Company

With reference to the above and in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby inform you that the Company had entered into a Share Purchase Agreement on 28th March, 2023 for the sale of Caplin Point Laboratories Colombia SAS - Colombia, a subsidiary of the Company, to Caplin Point Far East Limited – Hong Kong, a wholly – owned subsidiary of the Company.

Pursuant to execution of the Share Purchase Agreement and transfer of shares, Caplin Point Laboratories Colombia SAS - Colombia will cease to be a Subsidiary of the Company and shall become a step down Subsidiary of the Company through Caplin Point Far East Limited – Hong Kong.

Details required in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is attached as Annexure.

We request you to kindly take the above information on record.

Thanking You,

Sincerely yours,
For **Caplin Point Laboratories Limited**

Venkatram G
General Counsel & Company Secretary
Membership No. A23989

Disclosure for the proposed Sale of Subsidiary Company

S.NO	Particulars	Particulars		
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	As on 31st March, 2022 on Consolidated basis		
		Particular	Amount in actuals (INR)	Percentage
		Turnover	14,65,041	0.0001
		Net worth	(8,56,673)	(0.0001)
2	Date on which the agreement for sale has been entered into	28 th March, 2023		
3	The expected date of completion of sale/disposal	The transaction is expected to be completed on or before 31 st March, 2023, subject to achievement of closure as per the Share Purchase Agreement.		
4	Consideration received from such sale/disposal	The shares are being transferred at face value, which would result in the total consideration being USD 2,82,825 (at the prevailing exchange rate). The same would be received subject to the achievement of closure as per the Share Purchase Agreement.		
5	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	The sale is between Caplin Point Laboratories Limited and Caplin Point Far East Limited – Hong Kong, which is a wholly-owned subsidiary of the Company.		
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Yes, the transaction is between related parties i.e. the Company and its wholly-owned Subsidiary. The shares are being transferred at the Face Value which also satisfies the condition of Arm’s Length requirement.		
7	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable		